mazindol


Also found in: Wikipedia.

mazindol

 [ma´zin-dol]
a sympathomimetic amine having amphetamine-like actions; used as an oral appetite suppressant.

mazindol

/ma·zin·dol/ (ma´zin-dōl) a sympathomimetic amine having amphetamine-like actions; used as an anorectic.

mazindol

[mā′zindōl]
an anorexiant.
indication It is prescribed over a short term to decrease appetite in the treatment of exogenous obesity.
contraindications Glaucoma, history of drug abuse, concomitant use of a monoamine oxidase inhibitor, or known hypersensitivity to this drug prohibits its use.
adverse effects Among the more serious adverse effects are insomnia, palpitation, dizziness, dry mouth, tachycardia, and hypersensitivity reactions.

mazindol

An amphetamine-like sympathomimetic used as a short-term supplement to diet and exercise in managing obesity; it inhibits cocaine binding to dopamine transporters in the brain, but is ineffective in attenuating cocaine craving.
 
Adverse effects
Restlessness, tremor, tachypnoea, confusion, panic, aggressiveness, nausea, vomiting, diarrhoea, arrhythmias, seizures.

mazindol

Teronac Pharmacology An agent that inhibits cocaine binding to dopamine transporters in the brain. See Cocaine.

mazindol

(maz´indol´),
n brand names: Mazanor, Sanorex;
drug class: imidazoisoindole anorexiant (Controlled Substance Schedule IV);
action: has amphetamine-like activity and may have an effect on satiety center of the hypothalamus;
use: exogenous obesity.
References in periodicals archive ?
Aith and Dallari (35) analyzed the controversy relating to the Anvisa RDC no 52/2011 (36) that prohibited the use of anfepramone, fenproporex and mazindol, in harmony with the regulatory actions of Europe and the United States, and the debates held in the Brazilian Congress.
Data from NLS Pharma AG's mid-stage trial for its drug mazindol to treat attention deficit hyperactivity disorder (ADHD) showed it greatly reduced symptoms in adult patients, Reuters reported on Wednesday.
The IP portfolio acquired in this transaction includes mazindol, a non-amphetaminic psychostimulant.
El uso de psicoestimulantes (bupropion, dexanfetamina, metilfenidato, modafinil, mazindol, metanfetamina y selegiline) no ha demostrado efectos positivos en el tratamiento de dependencia a la cocaina (23).
1978) llevaron a cabo un estudio en el cual compararon los efectos del mazindol, el dietilpropion y un placebo con una terapia conductual en la reduccion de peso en pacientes obesos.
O femproporex, da mesma forma que o mazindol e a dietilpropiona, faz parte das medicacoes que podem ser usadas em pacientes que nao possuem condicoes de utilizar o orlistat e/ou sibutramina, naqueles nao responsivos a esse tratamento, ou naqueles em que esses medicamentos estao contra-indicados, segundo o II Consenso Latino-americano de Obesidade, revisado (Coutinho,1998).
6,10-15) Strategies include adjunctive antipsychotic medications, mood stabilisers and novel anticonvulsants, antidepressants such as selective serotonin re-uptake inhibitors and others, glycinergic agents, dopamine agonists, mazindol, omega-3 fatty acids and electroconvulsive therapy (ECT).
The most commonly encountered interacting agents amongst them would be chlorpromazine, clomipramine, diltiazem, dopamine, fluphenazine, labetalol, mazindol, nifedipine, promethazine and salbutamol which may affect MIBG's diagnostic and therapeutic efficacy.
La correlacion entre la rapida entrada de la cocaina y su potencial adictivo ha sido demostrada cuando se ha comparado al mazindol y al GBR 12.
T] is rather long and covers many tropane, benztropine, piperazine, methylphenidate, mazindol, and phencyclidine derivatives, the majority of these compounds interact also with other monoamine transporters, primarily with the serotonine transporter.
In this study we investigated if PKC-dependent DAT phosphorylation and transport activity were affected by acute exposure of dopamine or the transport blockers such as cocaine, mazindol, GBR12909, or the cocaine analog CFT.
Besides the Decision challenged, the Commission also adopted two further Decisions on March 9, 2000 concerning the withdrawal of marketing authorisations for medicinal products for human use containing: clobenzorex, fenbutrazate, fenproporex, mazindol, mefenorex, norpseudoephedrine, phenmetrazine, phendimetrazine and propylhexedrine.